• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

增强型肝纤维化（ELF）检测用于肝纤维化分期的性能：一项荟萃分析。

The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.

作者信息

Xie Qingsong, Zhou Xiaohu, Huang Pengfei, Wei Jianfeng, Wang Weilin, Zheng Shusen

机构信息

Division of Hepatobilitary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Key Laboratory of Combined Multi- Organ Transplantation, Ministry of Public Health, Zhejiang Province, Hangzhou, China; Key laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China.

出版信息

PLoS One. 2014 Apr 15;9(4):e92772. doi: 10.1371/journal.pone.0092772. eCollection 2014.

DOI:10.1371/journal.pone.0092772
PMID:24736610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3988013/
Abstract

BACKGROUND

The enhanced liver fibrosis test (ELF) has been shown to accurately predict significant liver fibrosis in several liver diseases.

AIMS

To perform a meta-analysis to assess the performance of the ELF test for the assessment of liver fibrosis.

STUDY

Electronic and manual searches were performed to identify studies of the ELF test. After methodological quality assessment and data extraction, pooled estimates of the sensitivity, specificity, area under the receiver operating characteristic curve (AUROC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and summary receiver operating characteristics (sROC) were assessed systematically. The extent of heterogeneity and reasons for it were assessed.

RESULTS

Nine studies were identified for analysis. The pooled sensitivity, specificity, positive LR, negative LR, and DOR values of ELF test, for assessment of significant liver fibrosis, were 83% (95% CI=0.80-0.86), 73% (95% CI=0.69-0.77), 4.00 (95% CI=2.50-6.39), 0.24 (95% CI=0.17-0.34), and 16.10 (95% CI=8.27-31.34), respectively; and, for evaluation of severe liver fibrosis, were 78% (95% CI=0.74-0.81), 76% (95% CI=0.73-0.78), 4.39 (95% CI=2.76-6.97), 0.27 (95% CI=0.16-0.46), and 16.01 (95% CI: 7.15-35.82), respectively; and, for estimation of cirrhosis, were 80% (95% CI=0.75-0.85), 71% (95% CI=0.68-0.74), 3.13 (95% CI=2.01-4.87), 0.29 (95% CI=0.19-0.44), and 14.09 (95% CI: 5.43-36.59), respectively.

CONCLUSIONS

The ELF test shows good performance and considerable diagnostic value for the prediction of histological fibrosis stage.

摘要

背景

增强肝纤维化检测（ELF）已被证明能准确预测多种肝脏疾病中的显著肝纤维化。

目的

进行一项荟萃分析，以评估ELF检测在评估肝纤维化方面的性能。

研究

通过电子检索和人工检索来识别关于ELF检测的研究。在进行方法学质量评估和数据提取后，系统地评估了敏感性、特异性、受试者操作特征曲线下面积（AUROC）、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）和汇总受试者操作特征（sROC）的合并估计值。评估了异质性的程度及其原因。

结果

确定了9项研究进行分析。ELF检测用于评估显著肝纤维化的合并敏感性、特异性、阳性似然比、阴性似然比和诊断比值比分别为83%（95%CI = 0.80 - 0.86）、73%（95%CI = 0.69 - 0.77）、4.00（95%CI = 2.50 - 6.39）、0.24（95%CI = 0.17 - 0.34）和16.10（95%CI = 8.27 - 31.34）；用于评估严重肝纤维化的分别为78%（95%CI = 0.74 - 0.81）、76%（95%CI = 0.73 - 0.78）、4.39（95%CI = 2.76 - 6.97）、0.27（95%CI = 0.16 - 0.46）和16.01（95%CI：7.15 - 35.82）；用于评估肝硬化的分别为80%（95%CI = 0.75 - 0.85）、71%（95%CI = 0.68 - 0.74）、3.13（95%CI = 2.01 - 4.87）、0.29（95%CI = 0.19 - 0.44）和14.09（95%CI：5.43 - 36.59）。

结论

ELF检测在预测组织学纤维化分期方面表现良好，具有相当大的诊断价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/c0648a717ca8/pone.0092772.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/4a572608fe93/pone.0092772.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/d660a572aafe/pone.0092772.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/0e6465ffe93a/pone.0092772.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/807578221ff8/pone.0092772.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/6526eec20f03/pone.0092772.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/77443d0c3603/pone.0092772.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/4ffe22c19d75/pone.0092772.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/d46d93499608/pone.0092772.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/f4197fae9c08/pone.0092772.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/ddf0c0165dd4/pone.0092772.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/c0648a717ca8/pone.0092772.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/4a572608fe93/pone.0092772.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/d660a572aafe/pone.0092772.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/0e6465ffe93a/pone.0092772.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/807578221ff8/pone.0092772.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/6526eec20f03/pone.0092772.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/77443d0c3603/pone.0092772.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/4ffe22c19d75/pone.0092772.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/d46d93499608/pone.0092772.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/f4197fae9c08/pone.0092772.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/ddf0c0165dd4/pone.0092772.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e632/3988013/c0648a717ca8/pone.0092772.g011.jpg

相似文献

1
The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.增强型肝纤维化（ELF）检测用于肝纤维化分期的性能：一项荟萃分析。
PLoS One. 2014 Apr 15;9(4):e92772. doi: 10.1371/journal.pone.0092772. eCollection 2014.
2
Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.增强型肝纤维化试验在非酒精性脂肪性肝病患者中评估进展性肝纤维化的性能。
JAMA Netw Open. 2021 Sep 1;4(9):e2123923. doi: 10.1001/jamanetworkopen.2021.23923.
3
Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases.荟萃分析：增强型肝纤维化检测用于诊断慢性肝病中的肝纤维化。
Aliment Pharmacol Ther. 2023 Apr;57(7):750-762. doi: 10.1111/apt.17385. Epub 2023 Jan 17.
4
Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting staging liver fibrosis in chronic liver disease patients: A systematic review and meta-analysis.红细胞分布宽度与血小板比值预测慢性肝病患者肝纤维化分期的诊断准确性：一项系统评价和荟萃分析。
Medicine (Baltimore). 2019 Apr;98(14):e15096. doi: 10.1097/MD.0000000000015096.
5
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.增强型肝纤维化试验与 FibroTest、瞬时弹性成像和间接标志物在诊断酒精性肝病患者中晚期纤维化的准确性比较。
Gastroenterology. 2018 Apr;154(5):1369-1379. doi: 10.1053/j.gastro.2018.01.005. Epub 2018 Jan 6.
6
Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.增强型肝纤维化检测指标作为慢性丙型肝炎患者肝纤维化的预测指标
J Clin Gastroenterol. 2015 Mar;49(3):235-41. doi: 10.1097/MCG.0000000000000128.
7
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.增强型肝脏纤维化检测在慢性乙型肝炎感染患者肝纤维化识别中的表现及其与瞬时弹性成像的比较。
J Viral Hepat. 2014 Jun;21(6):430-8. doi: 10.1111/jvh.12161. Epub 2013 Aug 15.
8
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.瞬时弹性成像在肝纤维化分期中的应用：一项荟萃分析。
Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18.
9
Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis.系统评价：非侵入性检测对自身免疫性肝炎肝纤维化分期的诊断准确性。
Hepatol Int. 2019 Jan;13(1):91-101. doi: 10.1007/s12072-018-9907-5. Epub 2018 Nov 15.
10
Noninvasive Diagnostic Methods for the Assessment of Hepatic Fibrosis in Liver Transplant Recipients.肝移植受者肝纤维化无创性诊断方法。
Transplant Proc. 2022 May;54(4):1042-1048. doi: 10.1016/j.transproceed.2022.02.034. Epub 2022 Jun 2.

引用本文的文献

1
Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.纤维化疾病：从信号通路、生物标志物到分子成像
Mol Imaging Biol. 2025 Aug 11. doi: 10.1007/s11307-025-02038-9.
2
Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.酒精使用障碍与酒精相关肝病：新定义、筛查与治疗
Gastroenterol Hepatol (N Y). 2024 Nov;20(11):662-671.
3
Characterization of an At-Risk Population for Nonalcoholic Fatty Liver Disease (NAFLD) in a Primary Care Setting Along the U.S.-Mexico Border.

本文引用的文献

1
Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis.金属蛋白酶组织抑制剂、肝星状细胞与肝纤维化
J Gastroenterol Hepatol. 1998 Sep;13(S1):S33-S38. doi: 10.1111/jgh.1998.13.s1.33.
2
Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B.瞬时弹性成像技术无创算法检测慢性乙型肝炎肝纤维化及肝硬度的研究进展
Aliment Pharmacol Ther. 2014 Jan;39(2):197-208. doi: 10.1111/apt.12559. Epub 2013 Nov 21.
3
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
美国-墨西哥边境基层医疗环境中，非酒精性脂肪性肝病（NAFLD）高危人群的特征分析
J Transcult Nurs. 2025 Jan;36(1):92-102. doi: 10.1177/10436596241271265. Epub 2024 Aug 27.
4
Chronic Liver Disease - What's New?慢性肝脏疾病 - 有何新进展？
Indian J Pediatr. 2024 Apr;91(4):391-397. doi: 10.1007/s12098-023-04819-y. Epub 2023 Sep 22.
5
Gas6 in chronic liver disease-a novel blood-based biomarker for liver fibrosis.慢性肝病中的Gas6——一种新型的基于血液的肝纤维化生物标志物。
Cell Death Discov. 2023 Aug 2;9(1):282. doi: 10.1038/s41420-023-01551-6.
6
Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?在初级保健中识别非酒精性脂肪性肝病患者：方法及益处何在？
J Clin Med. 2023 Jun 12;12(12):4001. doi: 10.3390/jcm12124001.
7
A salivary biomarker panel to detect liver cirrhosis.一种用于检测肝硬化的唾液生物标志物组合。
iScience. 2023 Jun 5;26(7):107015. doi: 10.1016/j.isci.2023.107015. eCollection 2023 Jul 21.
8
Towards an adiposity-related disease framework for the diagnosis and management of obesities.朝向肥胖相关疾病的诊断与管理框架。
Rev Endocr Metab Disord. 2023 Oct;24(5):795-807. doi: 10.1007/s11154-023-09797-2. Epub 2023 May 10.
9
Recent advances in NAFLD: current areas of contention.非酒精性脂肪性肝病的最新进展：当前的争议领域
Fac Rev. 2023 May 2;12:10. doi: 10.12703/r/12-10. eCollection 2023.
10
Emerging Biomarkers in Alcohol-associated Hepatitis.酒精性肝炎中的新兴生物标志物
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):103-115. doi: 10.1016/j.jceh.2022.07.246. Epub 2022 Aug 1.
ELFG 试验对慢性丙型肝炎肝纤维化无创性标志物诊断算法的贡献。
PLoS One. 2013;8(3):e59088. doi: 10.1371/journal.pone.0059088. Epub 2013 Mar 21.
4
The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.增强型肝脏纤维化（ELF）评分：正常值、影响因素和建议截断值。
J Hepatol. 2013 Aug;59(2):236-42. doi: 10.1016/j.jhep.2013.03.016. Epub 2013 Mar 21.
5
Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea.韩国健康体检人群和活体肝移植供者中正常的增强型肝纤维化（ELF）值。
Liver Int. 2013 May;33(5):706-13. doi: 10.1111/liv.12136. Epub 2013 Mar 12.
6
Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.经肝活检控制的肝纤维化分期与瞬时弹性成像（TE）比较的增强型肝纤维化（ELF）评分。
PLoS One. 2012;7(12):e51906. doi: 10.1371/journal.pone.0051906. Epub 2012 Dec 19.
7
Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.前瞻性验证 ELF 试验与 Fibroscan 和 FibroTest 在亚洲慢性乙型肝炎患者中预测肝纤维化的比较。
PLoS One. 2012;7(7):e41964. doi: 10.1371/journal.pone.0041964. Epub 2012 Jul 27.
8
Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C.独立验证增强型肝脏纤维化（ELF）评分在慢性丙型肝炎 ANRS HC EP 23 Fibrostar 队列患者中的应用。
Clin Chem Lab Med. 2012 Jan 13;50(4):693-9. doi: 10.1515/cclm-2011-0858.
9
Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?肝纤维化的生物标志物：在接收者操作特性曲线之下是什么？
Hepatology. 2011 Oct;54(4):1454-62. doi: 10.1002/hep.24515. Epub 2011 Aug 9.
10
Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency.无症状 ZZ 型α1-抗胰蛋白酶缺乏个体中增强型肝纤维化血浆标志物的表现。
Eur J Gastroenterol Hepatol. 2011 Aug;23(8):716-20. doi: 10.1097/MEG.0b013e328347daaf.